410 related articles for article (PubMed ID: 15362960)
1. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.
Ashwell SG; Bevan JS; Edwards OM; Harris MM; Holmes C; Middleton MA; James RA
Eur J Endocrinol; 2004 Apr; 150(4):473-80. PubMed ID: 15080776
[TBL] [Abstract][Full Text] [Related]
4. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
5. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
[TBL] [Abstract][Full Text] [Related]
7. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.
van Thiel SW; Romijn JA; Biermasz NR; Ballieux BE; Frölich M; Smit JW; Corssmit EP; Roelfsema F; Pereira AM
Eur J Endocrinol; 2004 Apr; 150(4):489-95. PubMed ID: 15080778
[TBL] [Abstract][Full Text] [Related]
8. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
Caron P
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
[TBL] [Abstract][Full Text] [Related]
9. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
[TBL] [Abstract][Full Text] [Related]
10. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
[TBL] [Abstract][Full Text] [Related]
12. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
13. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide.
Kelly P; Maher KT; Chew SL; Monson JP; Grossman AB; Jenkins PJ
Endocr Pract; 2010; 16(2):191-7. PubMed ID: 19833584
[TBL] [Abstract][Full Text] [Related]
14. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
Gutt B; Bidlingmaier M; Kretschmar K; Dieterle C; Steffin B; Schopohl J
Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):139-44. PubMed ID: 15789272
[TBL] [Abstract][Full Text] [Related]
15. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
Neggers SJ; Pronin V; Balcere I; Lee MK; Rozhinskaya L; Bronstein MD; Gadelha MR; Maisonobe P; Sert C; van der Lely AJ;
Eur J Endocrinol; 2015 Sep; 173(3):313-23. PubMed ID: 26047625
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
18. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
19. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.
Melmed S; Cook D; Schopohl J; Goth MI; Lam KS; Marek J
Pituitary; 2010; 13(1):18-28. PubMed ID: 19639415
[TBL] [Abstract][Full Text] [Related]
20. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]